All In Biotech

NDA 019667 · Novartis

Sandostatin

Octreotide Acetate · Injection

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jul 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1988

Oct 21, 1988

Approved uses

2

Original approval plus efficacy supplements

Registered trials

283

74 Phase 3, 26 recruiting

FAERS reports

9,636

7,955 serious, 1,880 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 22, 2026.

Sandostatin Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) Vasoactive Intestinal Peptide Tumors (VIPomas) : For the treatment of profuse watery diarrhea associated with VIP-secreting tumors. ( 1.3 ) Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Sandostatin Injection; these trials were not optimally designed to detect such effects. ( 1.4 ) 1.1 Acromegaly Sandostatin Injection is indicated to reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. 1.2 Carcinoid Tumors Sandostatin Injection is indicated for treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. 1.3 Vasoactive Intestinal Peptide Tumors Sandostatin Injection is indicated for the treatment of the profuse watery diarrhea associated with vasoactive intestinal peptide tumors (VIPomas)-secreting tumors. 1.4 Important Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in...

Mechanism: Sandostatin Injection exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of GH, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses luteinizing hormone (LH) response to gonadotropin releasing hormone (GnRH), decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, VIP, secretin, motilin, and pancreatic polypeptide. By virtue of these pharmacological actions, octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and VIP...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 3, 1994 Supplement 17 · Efficacy
  • Oct 21, 1988 Original approval · Type 1 - New Molecular Entity · priority review
5 products under this application
  • SANDOSTATIN · OCTREOTIDE ACETATE EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • SANDOSTATIN · OCTREOTIDE ACETATE EQ 0.5MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • SANDOSTATIN · OCTREOTIDE ACETATE EQ 0.05MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • SANDOSTATIN · OCTREOTIDE ACETATE EQ 0.2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • SANDOSTATIN · OCTREOTIDE ACETATE EQ 0.1MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Octreotide" as an intervention, any sponsor and status, largest first.

All 283 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea2,155
  • fatigue1,847
  • blood pressure increased1,658
  • nausea1,529
  • blood pressure systolic increased1,409
  • malaise1,232
  • abdominal pain1,227
  • death1,219
  • pain1,197
  • injection site pain1,138
  • asthenia1,064
  • weight decreased1,043

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004111
2005101
2006119
2007102
2008144
2009187
2010291
2011319
2012346
2013255
2014372
2015559
2016531
2017649
2018795
20191,050
20201,100
2021602
2022561
2023526
2024402
2025271
2026243

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sandostatin (Octreotide Acetate)

2024 spending

$197K

Beneficiaries

35

102 claims

Per beneficiary

$5,627

$25.52 per unit

View as table
YearSpending
2020$249,704
2021$247,190
2022$199,576
2023$169,357
2024$196,939

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,173 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.